Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Hepion Pharmaceuticals, Inc. | hepa-20210331.htm |
| EX-32.2 - EX-32.2 - Hepion Pharmaceuticals, Inc. | hepa-2021033110qxexx322.htm |
| EX-31.2 - EX-31.2 - Hepion Pharmaceuticals, Inc. | hepa-2021033110qxexx312.htm |
| EX-31.1 - EX-31.1 - Hepion Pharmaceuticals, Inc. | hepa-2021033110qxexx311.htm |
EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
HEPION PHARMACEUTICALS, INC.
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2021
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I am the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended March 31, 2021 and filed with the Securities and Exchange Commission (“Form 10-Q”).
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: May 14, 2021 | /s/ Robert Foster | ||||
| Robert Foster | |||||
| Chief Executive Officer and Director | |||||
| (Principal Executive Officer) | |||||